Clinigen Group plc Clinigen acquires global rights to Imukin®

TIDMCLIN

Clinigen Group plc

25 July 2018

RNS Reach

25 July 2018

Clinigen acquires global rights to Imukin(R)

from Horizon Pharma

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has acquired the global rights to Imukin(R) (recombinant human interferon gamma-1b) from Horizon Pharma plc ('Horizon'). Horizon will retain the rights to Actimmune(R) (recombinant human interferon gamma-1b) in the US, Canada and Japan.

Imukin(R) is licensed in 19 countries globally to reduce the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD) and for the treatment of Severe Malignant Osteopetrosis (SMO), both considered rare conditions.

Clinigen will revitalise Imukin(R) by working with healthcare professionals to ensure its benefits to patients are well understood. The Group will also make the medicine available to those who need it through the Group's global distribution network for both licensed and unlicensed supply.

Imukin(R) is the second global acquisition of a biologic by Clinigen following the acquisition of the global rights (outside the US) of Proleukin(R) from Novartis on 17 July 2018.

Shaun Chilton, Group Chief Executive Officer, Clinigen, said:

"Imukin(R) strengthens our commercial offering and represents a good strategic fit with our medicines portfolio growth strategy focused on products in oncology and rare diseases."

David Bryant, Chief Business Officer, Clinigen, said:

"Our second acquisition in recent weeks delivers on our long term strategy of acquiring global rights to assets with the aim of revitalising and returning them back to the broadest possible access."

- Ends -

Contact details

 
 Clinigen Group plc                             Tel: +44 (0) 1283 495010 
 David Bryant, Chief Business Officer 
 Matt Parrish, Head of Investor Relations 
 
 Numis Securities Limited                       Tel: +44 (0) 20 7260 1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
  James Black / Tom Ballard (Corporate 
  Broking) 
 
 RBC Capital Markets - Joint Broker             Tel: +44 (0) 20 7653 4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                            Tel: +44 (0) 20 7457 2020 
 Melanie Toyne-Sewell / Alex Shaw /             Email: clinigen@instinctif.com 
  Deborah Bell

Notes to Editors

About Imukin(R) (recombinant human interferon gamma-1b)

Interferon gamma is a cytokine with antiviral and immunomodulating effects. Interferon gamma-1b is used for its action as a macrophage-stimulating factor as an adjunct to antimicrobial therapy in chronic granulomatous disease. It is also used to reduce the frequency of serious infections in patients with severe malignant osteopetrosis.

About Chronic Granulomatous Disease (CGD)

Chronic granulomatous disease is a heterogeneous group of inherited disorders characterized by recurrent pyogenic infections that usually begin early in life and may lead to death in childhood. The incidence of CGD in the United States and Europe is around 1 in 200,000 to 1 in 250,000 live births, however the incidence varies significantly worldwide. Although the genetic basis for this disease is well known, the expected clinical course and outcome have only partially been defined, owing to its sporadic occurrence.

About Severe Malignant Osteopetrosis (SMO)

Osteopetrosis is an orphan disease, typically present during childhood, and if untreated, most patients die during the first decade of life due to recurrent infections. Approximately 70% of these patients die before the age of 6 years. Malignant or infantile autosomal recessive osteopetrosis is a rare but severe disorder with an average incidence of 1:300 000.

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinical Trial Services

Clinigen is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials.

Unlicensed Medicines

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides 'on demand' access globally to medicines which remain unlicensed at the point of care.

Commercial Medicines

Clinigen acquires global rights to niche hospital only and critical care products, revitalising these assets around the world and returning them back to sustained growth. It also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

The Group also has an 'unlicensed to licensed' strategy, where it looks to take unlicensed medicines with commercial potential and licence them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions.

For more information on Clinigen, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUSSVRWBABUAR

(END) Dow Jones Newswires

July 25, 2018 02:01 ET (06:01 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024